EUCTR2006-005118-11-AT进行中（未招募）不适用
A phase 2 study of Pemetrexed versus Pemetrexed + Erlotinib in second line Treatment for NSCLC
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Histological or cytological diagnosis of NSCLC with locally advanced or metastatic disease (Stage IIIA, IIIB or IV at entry) that is not amenable to curative therapy
- •[2]Non-smoker and smoker patients
- •[3]At least one unidimensionally measurable lesion meeting RECIST criteria. Positron emission tomography (PET scans) and ultrasound are not allowed.
- •[4]Patients must have failed one prior platinum-based chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease. Chemotherapy must be completed at least 2 weeks prior to study enrollment and the patient must have recovered from the acute toxic effects of the regimen.
- •[5]Prior radiation therapy allowed to <25% of the bone marrow. Prior radiation to the whole pelvis or chest for the treatment of NSCLC is not allowed.
- •Prior radiotherapy must be completed at least 4 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. Lesions that have been irradiated cannot be included as sites of measurable disease unless clear tumor progression has been documented in this lesion since the end of radiation therapy.
- •[6]At least 4 weeks since any prior surgery. Patients who, in the opinion of the investigator, have fully recovered from surgery in less than 4 weeks may also be considered for the study.
- •[7]Performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Scale
- •[8]Estimated life expectancy of at least 8 weeks.
- •[9]Patient compliance and geographic proximity that allow adequate follow-up.
- •[10]Adequate organ function including the following:
- •Adequate bone marrow reserve: Absolute neutrophils (segmented and bands) count (ANC) > or =1.5 x 109/L, platelets > or =100 x 109/L, and hemoglobin > or = 9 g/dL
- •Hepatic: Bilirubin < or = 1.5 x ULN, alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) < or = 3 x ULN (AP, AST and ALT •Renal: Calculated creatinine clearance (CrCl) > or = 45 mL/min based on the standard Cockcroft and Gault formula and serum creatinine <1.5 x ULN
- •[11]Signed informed consent from patient.
- •[12]Males or females at least 18 years of age.
- •[13]For women: Must be surgically sterile, post-menopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding.
- •For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[14]Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[15]Prior exposure to agents directed at the HER axis (e.g., Gefitinib, Erlotinib, Cetuximab, or Trastuzumab).
- •[16]Prior exposure to agents directed at Pemetrexed molecular targets (i.e., TS or DHFR inhibitors).
- •[17]Any known significant ophthalmologic abnormalities of the surface of the eye (The use of contact lenses is not recommended).
- •[18]Erlotinib and Pemetrexed are contraindicated in patients who have a history of severe hypersensitivity reaction to Erlotinib or Pemetrexed or to any other ingredient used in the formulation.
- •[19]Recent (within 30 days of enrolment) or concurrent yellow fever vaccination
- •[20]Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease.
- •[21]Patients under therapy with warfarin or coumarin derivatives.
- •[22]Pregnancy / Breast-feeding.
- •[23]Have a serious concomitant systemic disorder (e.g., active infection including HIV, or cardiac disease) that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol.
- •[24]Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- •[25]Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin doses < or =1.3 grams per day, for a 5-day period (8-day period for long-acting agents such as piroxicam).
- •[26]Brain metastasis. Patients who are symptomatic for brain metastasis must have a pretreatment CT or MRI of the brain. A patient with documented brain metastasis at the time of study entry will be excluded from entering in the study. Patients with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.
- •[27]Presence of clinically detectable (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
- •[28]Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease as defined by the New York Heart Association Class III or IV.
- •[29]Concurrent administration of any other antitumor therapy.
- •[30]Inability or unwillingness to take folic acid or vitamin B12 supplementation.
- •[31]Inability to take corticosteroids.
研究者
相似试验
进行中（未招募）
不适用
A phase 2 study of Pemetrexed versus Pemetrexed + Erlotinib in second line Treatment for NSCLCEUCTR2006-005118-11-HUEli lilly and Company Limited150
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLCEUCTR2006-005118-11-SEEli lilly and Company Limited200
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLCPatients who have histologically or cytologically documented diagnosis of nonsquamous NSCLC (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen for locally advanced or metastatic disease, who are considered for second line therapy and who meet the other disease criteria.MedDRA version: 8.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-005118-11-DEEli lilly and Company Limited200
招募中
2 期
A randomized phase II study of pemetrexed versus pemetrexed plus carboplatin in chemotherapy-naive elderly patients with IIIB/IV non-squamous non-small cell lung cancer.JPRN-UMIN000006129Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University60
进行中（未招募）
不适用
Randomized phase II study of pemetrexed versus pemetrexed and carboplatin as second line chemotherapy in advanced non-small-cell lung cancer (NSCLC). - NDPreviously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).MedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-004009-24-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA